MA2 Observation of Persistence Rates and Potential Cost Savings Associated With Certolizumab Pegol Treatment for Rheumatoid Arthritis in England, Wales and Northern Ireland Clinical Practice
Nov 1, 2012, 00:00
10.1016/j.jval.2012.08.499
https://www.valueinhealthjournal.com/article/S1098-3015(12)02212-7/fulltext
Title :
MA2 Observation of Persistence Rates and Potential Cost Savings Associated With Certolizumab Pegol Treatment for Rheumatoid Arthritis in England, Wales and Northern Ireland Clinical Practice
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(12)02212-7&doi=10.1016/j.jval.2012.08.499
First page :
A282
Section Title :
Medication Adherence Research
Open access? :
No
Section Order :
26